Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Point/Counterpoint: The Case for AstraZeneca

Stock MarketsNov 28, 2020 07:33AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters

By Geoffrey Smith and Peter Nurse

Investing.com-- AstraZeneca PLC (LON:AZN) is in a race to develop an effective Covid-19 vaccine, but that's not it's only goal.

It's really known as a global leader in cancer treatments, winning a number of drug approvals in recent years by regulators around the world. 

Earlier this week, the U.K.-based drug maker said late-stage trials of its Covid-19 vaccine showed 90% efficacy, but it quickly had to acknowledge flaws in the data. 

Investing.com's Geoffrey Smith and explains why this rare misstep won't cause lasting damage, while Peter Nurse says the fall-out has real reputational risks that will weigh on valuation. This is Point/Counterpoint.

The Bull Case

The bull case for AstraZeneca doesn’t need any contribution from the experimental vaccine for Covid-19.

The fact is that the company is a global powerhouse for oncology drugs and others that treat chronic diseases of the lungs and kidneys. It earns gross margins of 80% in a normal year and it expects its underlying earnings per share to grow by between 15% and 20% in 2020, a year when the world’s healthcare systems have had trouble finding resources for anything but treating Covid-19. 

It is, beyond any reasonable doubt, a well-run company, whose shares deserve a management premium. In barely seven years as CEO, Pascal Soriot had raised the market value of an already mature business by 150% when the pandemic erupted.  Soriot has quickly addressed this week’s misstep over communicating stage 2 trial results by ordering a new trial, as any responsible CEO might.

Global regulators have been pleased to approve a string of its drugs in recent years, and suggestions that this vital relationship will be damaged by an imperfect trial conducted under the extraordinary pressures of the current race for a Covid cure are alarmist.  

Barring a fiasco wholly out of character with the rest of Soriot’s career, there is no downside risk for the share price even if the Covid-19 drug falls short. AstraZeneca’s share price is almost exactly where it was at the start of the year, before anyone had even heard the dreaded C-word.  Given that the cost of servicing its sizable debt pile has come down sharply since then (allowing a higher stock valuation, all other things being equal), you can even argue that the market is already applying a discount to the shares for the whole Covid-19 saga.

Either the drug is a write-off, in which case much of the cost remains with the governments that have helped to fund its development, or it actually is effective, allowing worldwide distribution. In the latter case, the fact that it has agreed to provide the drug at no profit should not be seen as the bugbear that many investors consider it. Reports citing confidential contracts with manufacturers suggest that AZ will be able to exercise pricing power from the second half of next year already.

And if it does eschew the short-term profit by keeping the price down, the long-term benefit could still be considerable.  Cancer, its true specialism, is a rich country disease, so the spread of wealth across ever more parts of the world is a secular positive for it. The gain in goodwill from not price-gouging on the drug everyone wants and needs will be intangible, but immeasurable.

The Bear Case

The bear case surrounding AstraZeneca rests largely on valuation and on the reputational damage it may incur from the mess it’s making of getting its coronavirus vaccine candidate approved.

With a P/E ratio of around 55, the company’s stock is priced well above both the industry average and its historical norm, suggesting there is plenty of downside potential.

The pharmaceutical giant released interim analysis of late-stage trials of its vaccine to great fanfare on Monday, stating that its efficacy reached a maximum of 90% depending on the dosage regime.

However, doubts quickly emerged over the reliability of the data provided by AstraZeneca and its partner, the University of Oxford, as regards the drug’s effectiveness.

Importantly, Moncef Slaoui, the head of the U.S. Operation Warp Speed team tasked with funding vaccine development, pointed out a potential flaw, saying the subgroup which reported the highest degree of efficacy had been restricted to people under 55, subjects which are likely to be more resistant to the disease.

Geoffrey Porges, Director of Therapeutics Research at life sciences boutique investment bank SVB Leerink, has been widely reported as predicting that the vaccine will never be licensed in the U.S., particularly as there appear to be viable alternatives in the form of Pfizer Inc (NYSE:PFE)’s and Moderna Inc (NASDAQ:MRNA)’s drugs. Promising candidate vaccines from Johnson & Johnson (NYSE:JNJ) and others are still in the development pipeline.

AstraZeneca had promised to supply its vaccine at cost price for as long as the pandemic lasts, so not making it into the valuable American market for this product may not necessarily be a big thing. But the botched communication of what was far too small a trial could be far more difficult to ignore, doing lasting damage to its relationship with the all-important Food & Drug Administration. After all, it generated almost $8 billion in revenue in the U.S. last year, its biggest single market by far.

Swiss banking giant UBS earlier this week kept its “sell” rating on AstraZeneca, citing the uncertainty surrounding its vaccine’s results. Earlier this month it had also noted that product sales in emerging markets disappointed in the third quarter results, whereas U.S. business surprised positively. This balance may be about to change.

Point/Counterpoint: The Case for AstraZeneca
 

Related Articles

World stocks at 1-month high as bond yields soften
World stocks at 1-month high as bond yields soften By Reuters - Oct 19, 2021 4

By Saikat Chatterjee LONDON (Reuters) - World stocks climbed to a one-month high on Tuesday as a rally in technology shares and prospects of solid corporate earnings helped...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (7)
Alan Rice
Alan Rice Nov 29, 2020 3:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
"Just say "Yes." (to drugs) ??
Styr Lotus
Styr Lotus Nov 28, 2020 5:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vaccines made in a hurry are very dangerous
hami Durmaz
hami Durmaz Nov 28, 2020 2:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
modernas vaccine more practical as usage storage delivery ...
Zohaib Zaman
Zohaib Zaman Nov 28, 2020 12:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nothing works all vaccines all peoples just thinking like dreamers
AL Bundy
AL Bundy Nov 28, 2020 12:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The vaccines are not going to do F all. Except make big pharma rich. Once the world realises the vaccines are only good for 6 months and covid mutates, the stock market will head to levels not seen since the GFC. What a joke that the vaccine magically appears after the election lol
Adrian White
Adrian White Nov 28, 2020 12:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No. The joke is that Trump tried to push them to be completed before the election rather than allowing the scientists to take the time necessary to make sure that they work, and that they're safe. Trump cared more about trying to look good before the election than about letting the scientists do things the right way.
Jo Pa
Jo Pa Nov 28, 2020 12:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
3 vaccines, each with record 95% efficacy, all announced just 1-2 weeks after election. Not suspicious at all.
Stephen Beckwith
Stephen Beckwith Nov 28, 2020 12:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s the implication in your mind?
Дмитрий Сильвестров
Дмитрий Сильвестров Nov 28, 2020 10:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
-20% by the end of 1H2021
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email